Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818806 | 0.77 | KCNMA1 (0.43) | ADORA1RAB9ATDP1ALDH1A1HPGD | |
| SCHEMBL8513179 | 0.77 | MGLL (0.37) | MGLLRAB9AALDH1A1PTGS1PTGS2 | |
| SCHEMBL1899917 | 0.73 | DRD4 (0.33) | ALDH1A1GRM4 | |
| SCHEMBL2902914 | 0.71 | NOTUM (0.41) | NOTUMADORA1MGLLMEN1KMT2A | |
| SCHEMBL1891782 | 0.69 | NOTUM (0.40) | NOTUMADORA1MGLLMEN1KMT2A | |
| SCHEMBL15657033 | 0.68 | NOTUM (0.47) | NOTUMMGLLKMT2ATDP1ALDH1A1 | |
| SCHEMBL2688702 | 0.68 | NOTUM (0.58) | NOTUMADORA1KCNN4ADORA3PTGS1 | |
| SCHEMBL1906385 | 0.67 | ADORA1 (0.42) | NOTUMADORA1MGLLMEN1KMT2A | |
| SCHEMBL29793813 | 0.67 | NOTUM (0.50) | NOTUMADORA1MGLLMEN1KMT2A | |
| SCHEMBL20605667 | 0.67 | NOTUM (0.50) | NOTUMADORA1MGLLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110300589-B | Bicyclic heteroaryl derivatives as CFTR potentiators | 囊性纤维化基金会 | 2023-03-10 | — | — | CN | disclosed |
| CN-114773314-A | Biarylaminoguanidine derivative | 上海拓界生物医药科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-110337294-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会治疗公司 | 2019-10-15 | — | — | CN | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| WO-2012070024-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2012-05-31 | — | — | WO | disclosed |
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | disclosed |
| CN-101541331-A | Novel macrolides and ketolides with antimicrobial activity | WOCKHARDT RESEARCH CENTER (IN) | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | NOTUM 99/4885ADORA1 4483/4885MGLL 155/4885 |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | CA7, CA4, CA2 | NOTUM 1354/4885ADORA1 2604/4885MGLL 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.